Intersect ENT, Inc. (NASDAQ:XENT)‘s stock had its “hold” rating reissued by research analysts at Northland Securities in a note issued to investors on Friday. They presently have a $25.00 price target on the medical equipment provider’s stock.

A number of other research firms have also weighed in on XENT. Canaccord Genuity increased their price target on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. Bank of America Corporation increased their price target on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Deutsche Bank AG set a $31.00 price target on Intersect ENT and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Intersect ENT has a consensus rating of “Buy” and a consensus target price of $29.00.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business had revenue of $22.31 million during the quarter, compared to analyst estimates of $21.53 million. During the same quarter last year, the company posted ($0.22) EPS. Intersect ENT’s revenue for the quarter was up 20.8% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/03/intersect-ents-xent-hold-rating-reiterated-at-northland-securities.html.

In other news, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $30.79, for a total transaction of $615,800.00. Following the completion of the sale, the insider now directly owns 525,868 shares in the company, valued at approximately $16,191,475.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $31.05, for a total value of $398,464.65. Following the sale, the chief financial officer now owns 27,833 shares of the company’s stock, valued at $864,214.65. The disclosure for this sale can be found here. Insiders have sold a total of 121,730 shares of company stock valued at $3,642,747 over the last 90 days. Corporate insiders own 13.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its holdings in shares of Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Intersect ENT during the 2nd quarter valued at about $205,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Intersect ENT during the 2nd quarter valued at about $229,000. Prudential Financial Inc. acquired a new stake in shares of Intersect ENT during the 2nd quarter valued at about $229,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Intersect ENT during the 2nd quarter valued at about $231,000. Institutional investors and hedge funds own 83.08% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.